» Articles » PMID: 28104709

Utility of Social Media and Crowd-sourced Data for Pharmacovigilance: a Scoping Review Protocol

Overview
Journal BMJ Open
Specialty General Medicine
Date 2017 Jan 21
PMID 28104709
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Adverse events associated with medications are under-reported in postmarketing surveillance systems. A systematic review of published data from 37 studies worldwide (including Canada) found the median under-reporting rate of adverse events to be 94% in spontaneous reporting systems. This scoping review aims to assess the utility of social media and crowd-sourced data to detect and monitor adverse events related to health products including pharmaceuticals, medical devices, biologics and natural health products.

Methods And Analysis: Our review conduct will follow the Joanna Briggs Institute scoping review methods manual. Literature searches were conducted in MEDLINE, EMBASE and the Cochrane Library from inception to 13 May 2016. Additional sources included searches of study registries, conference abstracts, dissertations, as well as websites of international regulatory authorities (eg, Food and Drug Administration (FDA), the WHO, European Medicines Agency). Search results will be supplemented by scanning the references of relevant reviews. We will include all publication types including published articles, editorials, websites and book sections that describe use of social media and crowd-sourced data for surveillance of adverse events associated with health products. Two reviewers will perform study selection and data abstraction independently, and discrepancies will be resolved through discussion. Data analysis will involve quantitative (eg, frequencies) and qualitative (eg, content analysis) methods.

Dissemination: The summary of results will be sent to Health Canada, who commissioned the review, and other relevant policymakers involved with the Drug Safety and Effectiveness Network. We will compile and circulate a 1-page policy brief and host a 1-day stakeholder meeting to discuss the implications, key messages and finalise the knowledge translation strategy. Findings from this review will ultimately inform the design and development of a data analytics platform for social media and crowd-sourced data for pharmacovigilance in Canada and internationally.

Registration Details: Our protocol was registered prospectively with the Open Science Framework (https://osf.io/kv9hu/).

Citing Articles

Professional Athletes' Well-Being: New Challenges in Post-COVID-19 Times.

Assa R, Reizer A Behav Sci (Basel). 2023; 13(10).

PMID: 37887481 PMC: 10604620. DOI: 10.3390/bs13100831.


Sleep medicine: Practice, challenges and new frontiers.

Parrino L, Halasz P, Szucs A, Thomas R, Azzi N, Rausa F Front Neurol. 2022; 13:966659.

PMID: 36313516 PMC: 9616008. DOI: 10.3389/fneur.2022.966659.


Factors related to help-seeking for cancer medical care among people living in rural areas: a scoping review.

Oshiro M, Kamizato M, Jahana S BMC Health Serv Res. 2022; 22(1):836.

PMID: 35765056 PMC: 9241203. DOI: 10.1186/s12913-022-08205-w.


Vulnerability assessment tools for infectious threats and antimicrobial resistance: a scoping review protocol.

Jeleff M, Lehner L, Giles-Vernick T, Duckers M, Napier A, Jirovsky E BMJ Open. 2019; 9(11):e031944.

PMID: 31740471 PMC: 6886976. DOI: 10.1136/bmjopen-2019-031944.


The Adverse Drug Reactions From Patient Reports in Social Media Project: Protocol for an Evaluation Against a Gold Standard.

Arnoux-Guenegou A, Girardeau Y, Chen X, Deldossi M, Aboukhamis R, Faviez C JMIR Res Protoc. 2019; 8(5):e11448.

PMID: 31066711 PMC: 6528435. DOI: 10.2196/11448.


References
1.
Stone P . Popping the (PICO) question in research and evidence-based practice. Appl Nurs Res. 2002; 15(3):197-8. DOI: 10.1053/apnr.2002.34181. View

2.
Bates D, Evans R, Murff H, Stetson P, Pizziferri L, Hripcsak G . Detecting adverse events using information technology. J Am Med Inform Assoc. 2003; 10(2):115-28. PMC: 150365. DOI: 10.1197/jamia.m1074. View

3.
Mittmann N, Knowles S, Gomez M, Fish J, Cartotto R, Shear N . Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis. Drug Saf. 2004; 27(7):477-87. DOI: 10.2165/00002018-200427070-00004. View

4.
van der Hooft C, Sturkenboom M, van Grootheest K, Kingma H, Stricker B . Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands. Drug Saf. 2006; 29(2):161-8. DOI: 10.2165/00002018-200629020-00006. View

5.
McClellan M . Drug safety reform at the FDA--pendulum swing or systematic improvement?. N Engl J Med. 2007; 356(17):1700-2. DOI: 10.1056/NEJMp078057. View